Health
Roche's Wilserdly Wins First FDA Approval in Advanced Breast Cancer
The all-oral regimen gives patients whose cancer stopped responding to hormone therapy a treatment they can take at home.
The FDA on Monday approved Roche's Wilserdly with everolimus for certain advanced breast cancers that stopped responding to hormone therapy, the drug's first U.S. clearance.
Genentech, a member of the Roche Group, announced the approval on Monday, November 16. The Food and Drug Administration (FDA) approved Wilserdly (giredestrant) in combination with everolimus.
Who the approval covers
The approval covers adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Locally advanced disease has spread nearby; metastatic disease has spread to other body parts.
Patients qualify when cancer recurred during or after endocrine-based adjuvant therapy, the treatment given after surgery. They also qualify after progression on at least one endocrine-based regimen in the metastatic setting.
Eligibility is detected by an FDA-authorized test for the ESR1 mutation. The FDA also authorized FoundationOne Liquid CDx, a blood-based test, as the companion diagnostic for identifying those mutations.
Wilserdly is an oral selective estrogen receptor degrader (SERD) and full antagonist. It blocks estrogen from binding its receptor, triggers the receptor protein's breakdown, and slows cancer-cell growth.
What the evERA trial showed
The approval rests on evERA, a Phase III trial in 373 adults after prior CDK4/6 inhibitor and endocrine therapy. CDK4/6 inhibitors are a standard breast-cancer drug class used alongside hormone therapy.
Patients received giredestrant 30 milligrams once daily plus everolimus 10 milligrams daily, in an arm of 183 patients. The comparator arm, 190 patients, received physician's-choice endocrine therapy - exemestane, fulvestrant or tamoxifen - plus everolimus.
Among 207 patients with ESR1-mutated tumors, median progression-free survival reached 10.0 months on the combination. Progression-free survival is the time before disease worsens or a patient dies; the comparator reached 5.5 months.
The hazard ratio was 0.38 (95% confidence interval 0.27 to 0.54), a 62% reduction in the risk of progression or death. The difference was statistically significant, at p below 0.0001.
Objective response rate, the share of patients whose tumors shrank measurably, was 27% on the combination against 14%. Overall survival data were immature at the analysis, so the approval rests on progression-free survival.
The trial results were published in The New England Journal of Medicine. evERA was randomized, open-label and multicenter, and ESR1 status was assessed centrally from circulating tumor DNA.
Safety and the label's warnings
The most common adverse reactions, each in at least 20% of patients, were stomatitis, rash, fatigue and diarrhea. Stomatitis is mouth sores; the list also includes musculoskeletal pain, pneumonitis and nausea.
Pneumonitis is lung inflammation, and musculoskeletal pain means muscle and joint pain. The prescribing information warns about bradycardia, a slow heart rate, and embryo-fetal toxicity, meaning harm to an unborn baby.
Levi Garraway, Genentech's chief medical officer, called resistance "a substantial challenge — often requiring more intensive treatment" for these patients. He said the all-oral regimen significantly delays progression and lets patients take treatment from home.
Erica L. Mayer of Dana-Farber Cancer Institute said the evERA regimen "directly targets the primary genomic drivers of resistance." She cited "prolonged disease control through a fully oral therapeutic option" for patients.
Why ESR1 mutations matter
Up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations. Those mutations drive resistance to endocrine therapy and disease progression, Genentech said.
Hormone receptor-positive, HER2-negative disease accounts for about 70% of breast cancer cases. Globally, 2.3 million women are diagnosed each year and 670,000 die from the disease.
Roche told Reuters the treatment will be priced at $22,500 per month. RBC Capital Markets analyst Trung Huynh said the price is broadly in line with Lilly's Inluriyo.
Huynh called the approval a key first step, noting the pending early-stage indication is the larger market. Genentech said Wilserdly should be available in the United States in the coming weeks.
What remains unknown
Whether Wilserdly improves overall survival is unknown; survival data were immature at the progression analysis. Longer follow-up will show whether the progression advantage becomes a survival advantage.
How payers cover a $22,500 monthly price is unanswered, and uptake against Lilly's competing oral option is unproven. How the heart-rate warning affects prescribing in routine practice is also unknown.
Whether the blood test identifies every eligible patient in routine practice is untested. In the trial, testing was central and limited to specific ESR1 mutations in the ligand-binding domain.
The decisions that come next
What to watch: the FDA's decision on Wilserdly as adjuvant, post-surgery, treatment for early-stage disease. The application is under Priority Review, with a Prescription Drug User Fee Act date of November 30, 2026.
Genentech says approval would make it the first new adjuvant endocrine therapy in over 20 years. Launch uptake and the maturing evERA survival data are the other tests to follow.
Sources & evidence
Source checked3 sources · 11 figures
Figure receipts
Sources
Sources used for this piece.
As of Tuesday, Nov. 17, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

